|
Friday, April 28, 2023, San Antonio, Texas, 6:00 AM – 7:30 AM Central Time (7:00 AM – 8:30 AM Eastern Time)
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial ParticipationFifteenth Annual RTP Symposium Series Held During the Annual ONS CongressHepatobiliary Cancers
Location
Grand Hyatt San Antonio River Walk 600 E Market Street San Antonio, TX 78205 Hotel Phone: (210) 224-1234 Program Schedule — Central Time 5:30 AM – 6:00 AM — Registration 6:00 AM – 7:30 AM — Breakfast Meeting Meeting Room Texas Ballroom (Salons A-C) – Fourth Floor This event will also be webcast live. Please see Registration tab for details. Faculty
Ahmed Omar Kaseb, MD, CMQ John E and Dorothy J Harris Professor in Gastrointestinal Cancer Research Member, National Hepatobiliary Task Force NCI, USA Tenured Professor and Director, Hepatocellular Carcinoma Program Director, MD Anderson HCC SPORE Editor-in-Chief Journal of Hepatocellular Carcinoma Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Blanca Ledezma, MSN, NP, AOCNP Nurse Practitioner III UCLA Santa Monica Hematology/Oncology UCLA Health Santa Monica, California Daneng Li, MD Associate Professor Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, California Amanda K Wagner, APRN-CNP, AOCNP GI Malignancies The James Cancer Hospital The Ohio State University Columbus, Ohio Moderator Neil Love, MD Research To Practice Miami, Florida Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Eisai Inc, Incyte Corporation, Merck, and Taiho Oncology Inc during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration 6:00 AM – 7:30 AM — Educational Breakfast Meeting What I Tell My Patients About ... First-Line Therapy with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma (HCC)
Up-Front Treatment with Dual Immune Checkpoint Inhibitor Therapy for HCC
The Role of Tyrosine Kinase Inhibitor (TKI) Monotherapy for Newly Diagnosed Advanced HCC
Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) HCC
Toxicities and Other Practical Considerations with Immune Checkpoint Inhibitor-Based Regimens for HCC
The Tolerability of Anti-angiogenic Agents Used in the Treatment of HCC
The Role of Immunotherapy in the Treatment of Biliary Tract Cancers
The Importance of Biomarker Testing for Patients with Advanced Biliary Tract Cancers
The Role of FGFR Inhibitors in the Management of Advanced Cholangiocarcinoma
Tolerability and Other Considerations with FGFR Inhibitors for Cholangiocarcinoma
The Role of Ivosidenib in Therapy for Advanced Cholangiocarcinoma
Other Promising Targeted Therapies for Advanced Biliary Tract Cancers
Target Audience
Accreditation Statement Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Ms Wagner has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Kaseb — Advisory Committee, Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck. Ms Ledezma — Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Lilly. Dr Li — Consulting Agreements: Coherus BioSciences, Delcath Systems Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Merck, Servier Pharmaceuticals LLC, TerSera Therapeutics LLC; Contracted Research: AstraZeneca Pharmaceuticals LP, Brooklyn ImmunoTherapeutics.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Incyte Corporation, Merck, and Taiho Oncology Inc. Grand Hyatt San Antonio River Walk Meeting Room: The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hepatobiliary cancers. IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 AM Central Time on Friday, April 28th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com. Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability. LIVE WEBCAST registration open to all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
|